Ablative Solutions, Inc. announced on 1/3/19 the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar... read more
Ablative Solutions, Inc. announced on 1/3/19 the first close of its $77 million Series D funding round. The round was led by new investor Gilde Healthcare and co-led by existing investor BioStar... read more
Wave Life Sciences Ltd. (NASDAQ: WVE announced on 1/3/19 that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne muscular dystrophy (DMD) clinical program has been selected for... read more
Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for MYO-102, a novel gene therapy candidate for alpha-... read more
Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed... read more
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide)... read more